Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab Compared to Deucravacitinib for Moderate Plaque Psoriasis
NCT06333860Phase 4Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2024
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 4 trial of risankizumab in plaque psoriasis, sponsored by AbbVie Inc.. Started May 2024; status: completed.
02
Drugs
risankizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06333860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06333860.